A live webcast of ACADIA's presentation willbe accessible on the company's website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through September 18, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is focused on developing aportfolio of its four most advanced product candidates, includingpimavanserin in Phase III for Parkinson'sdisease psychosis, a compound in Phase II for chronic pain and acompound in Phase I for glaucoma, both in collaboration with Allergan,and ACP-106 in IND-track development. All of the product candidates inACADIA's pipeline emanate from discoveriesmade using its proprietary drug discovery platform and are directed atindications with large unmet medical needs. ACADIA'scorporate headquarters is located in San Diego, California and itmaintains research and development operations in both San Diego and MalmA,Sweden.
SOURCE: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871